Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
alosertib
- Development stage
- Preclinical
- Lead developer
- Allinky Biopharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Alosertib (AIK3a-cc) is a first-in-class, oral small molecule inhibitor of interleukin 1 beta (IL-1β) production. Developed by Allinky Biopharma, it targets IL-1β, a key cytokine involved in immune and inflammatory responses. By inhibiting IL-1β production, alosertib aims to address autoinflammatory diseases as well as immune-mediated and non-immune mediated inflammatory conditions that currently lack effective treatment options. The drug is positioned as an innovative therapy for chronic inflammation and fibrosis[1][2][3].
- Other names
- AIK3a-ccAIK-3a-ccAIK 3a-cc
02
Targets
IL1B (Interleukin-1 beta)
Beyond the preview
Go deeper on alosertib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on alosertib.